Jean-Christophe Thibault
Research Subjects
Jean-Christophe Thibault has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Florence Cliquet
Nancy Laboratory for Rabies and Wildlife, ANSES, F-54220 Malzéville, France
4 shared publications - Hasanthi Rathnadiwakara
Department of Physiology, Faculty of Medicine, University of Colombo, Sri Lanka
4 shared publications - Mangala Gunatilake
University of Colombo
4 shared publications - Marine Wasniewski
Nancy Laboratory for Rabies and Wildlife, ANSES
4 shared publications - Mayuri Geethanjalie Thammitiyagodage
Animal Centre, Medical Research Institute, Colombo, Sri Lanka
3 shared publications - Mohamed Ijas
Municipal Veterinary Department, Colombo Municipal Council, Colombo, Sri Lanka
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 15 (2) , 151-166
Immunogenicity of anti-rabies vaccines (ARVs) marketed in Sri Lanka: a comparative study
Several brands of anti-rabies vaccines (ARVs) are used for dog vaccination in Sri Lanka, which have shown major differences in their potency levels. This comparative study was conducted to determine humoral immune response of these ARVs using 2 different animal species. The reliability of an enzyme-linked immunosorbent assay (ELISA) antibody kit was assessed in comparison to the standard Fluorescent Antibody Virus Neutralization (FAVN) test. The laboratory animal study was conducted using 3–4 months old sero-negative New Zealand White rabbits. Nine vaccines from 7 producers were tested including 8 monovalent inactivated ARVs: Canvac R® single-dose and multi-dose, Nobivac® Rabies, Rabies Killed® Vaccine, Rabisin®, Defensor 3®, Raksharab® single-dose and multidose, and one bivalent inactivated ARV, Nobivac® RL. Second part was conducted in field dogs. Four vaccines with the highest potencies were selected for this field dog study. Animals were vaccinated subcutaneously with one dose of a selected ARV. Day 0 blood samples were collected just before the vaccination and Day 7, Day 14, and Day 30 samples from rabbits and Day 30 samples from dogs were collected post-vaccination. Significant differences of humoral immune response between different vaccines brands were observed in both animal species. The coefficient of concordance between the FAVN test and the ELISA was 54.6% and 85.3% for rabbits and dogs respectively. The overall results showed that ARVs with proven potency can induce a robust humoral immune response following vaccination. There was a comparatively higher agreement between the FAVN test and the ELISA.
- 1 January 2026
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 15 (2) , 151-166
Open AccessImmunogenicity of anti-rabies vaccines (ARVs) marketed in Sri Lanka: a comparative study
Several brands of anti-rabies vaccines (ARVs) are used for dog vaccination in Sri Lanka, which have shown major differences in their potency levels. This comparative study was conducted to determine humoral immune response of these ARVs using 2 different animal species. The reliability of an enzyme-linked immunosorbent assay (ELISA) antibody kit was assessed in comparison to the standard Fluorescent Antibody Virus Neutralization (FAVN) test. The laboratory animal study was conducted using 3–4 months old sero-negative New Zealand White rabbits. Nine vaccines from 7 producers were tested including 8 monovalent inactivated ARVs: Canvac R® single-dose and multi-dose, Nobivac® Rabies, Rabies Killed® Vaccine, Rabisin®, Defensor 3®, Raksharab® single-dose and multidose, and one bivalent inactivated ARV, Nobivac® RL. Second part was conducted in field dogs. Four vaccines with the highest potencies were selected for this field dog study. Animals were vaccinated subcutaneously with one dose of a selected ARV. Day 0 blood samples were collected just before the vaccination and Day 7, Day 14, and Day 30 samples from rabbits and Day 30 samples from dogs were collected post-vaccination. Significant differences of humoral immune response between different vaccines brands were observed in both animal species. The coefficient of concordance between the FAVN test and the ELISA was 54.6% and 85.3% for rabbits and dogs respectively. The overall results showed that ARVs with proven potency can induce a robust humoral immune response following vaccination. There was a comparatively higher agreement between the FAVN test and the ELISA.
- Open Access
- 25 September 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (10) , 1946
Isolation of Virulent Leptospira Serogroup Australis Field Strains from Symptomatic Dogs for Canine Leptospiral Vaccine Development
Leptospirosis is a widespread zoonosis caused by spirochaetes belonging to the pathogenic species of Leptospira, which are classified into more than 25 serogroups and 250 serovars. Vaccination can prevent the disease in dogs but offers incomplete efficacy because of a lack of cross-protection between serogroups. The aim of this study was to validate a robust recruitment and sampling process, with the objectives of isolating and typing circulating Leptospira pathogenic strains and then selecting those of proven virulence and pathogenicity for vaccine development. Blood and urine samples from dogs with clinical syndromes compatible with acute leptospirosis were sterilely collected and transported to a reference laboratory for a micro-agglutination test (MAT), PCR, and bacterial isolation. Isolated strains underwent molecular typing using RNA16S, variable-number tandem repeat (VNTR), and pulsed-field gel electrophoresis (PFGE). Subtyping was performed using core genome multilocus sequence typing (CgMLST). Among 64 included dogs, 41 had MAT and/or PCR results compatible with Leptospira infection, and 14 Leptospira strains were isolated. Based on molecular typing, 11 isolates were classified as L. interrogans serogroup Australis, serovar Bratislava, and 3 as serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae. CgMLST subtyping revealed a diversity of clonal groups (CGs) distributed in several regional clusters. Besides validating a robust recruitment and sampling process, this study outlines the value of combining PCR and serological testing when suspecting leptospirosis and the usefulness of implementing molecular typing methods to identify circulating field strains. It also confirms the epidemiological importance of the Australis serogroup and allows for the collection of different highly pathogenic strains for vaccine development.
- 25 September 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (10) , 1946
Open AccessIsolation of Virulent Leptospira Serogroup Australis Field Strains from Symptomatic Dogs for Canine Leptospiral Vaccine Development
Leptospirosis is a widespread zoonosis caused by spirochaetes belonging to the pathogenic species of Leptospira, which are classified into more than 25 serogroups and 250 serovars. Vaccination can prevent the disease in dogs but offers incomplete efficacy because of a lack of cross-protection between serogroups. The aim of this study was to validate a robust recruitment and sampling process, with the objectives of isolating and typing circulating Leptospira pathogenic strains and then selecting those of proven virulence and pathogenicity for vaccine development. Blood and urine samples from dogs with clinical syndromes compatible with acute leptospirosis were sterilely collected and transported to a reference laboratory for a micro-agglutination test (MAT), PCR, and bacterial isolation. Isolated strains underwent molecular typing using RNA16S, variable-number tandem repeat (VNTR), and pulsed-field gel electrophoresis (PFGE). Subtyping was performed using core genome multilocus sequence typing (CgMLST). Among 64 included dogs, 41 had MAT and/or PCR results compatible with Leptospira infection, and 14 Leptospira strains were isolated. Based on molecular typing, 11 isolates were classified as L. interrogans serogroup Australis, serovar Bratislava, and 3 as serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae. CgMLST subtyping revealed a diversity of clonal groups (CGs) distributed in several regional clusters. Besides validating a robust recruitment and sampling process, this study outlines the value of combining PCR and serological testing when suspecting leptospirosis and the usefulness of implementing molecular typing methods to identify circulating field strains. It also confirms the epidemiological importance of the Australis serogroup and allows for the collection of different highly pathogenic strains for vaccine development.
- Open Access
- 29 December 2023
- Published by The Physiological Society of India in INDIAN JOURNAL OF PHYSIOLOGY AND ALLIED SCIENCES
- Vol. 75 (04) , 47-56
Determination of immunogenicity and potency of canine anti-rabies vaccines marketed in Sri Lanka: A Proposal on an experimental study using rabbits as the animal model and field study using sample dog population.
Anti-rabies vaccines (ARVs) with good immunogenic capacity play an important role in controlling the deadly zoonotic rabies in Sri Lanka. The ARVs currently marketed in the country have not been tested for their efficacy and potency at the local level before being released to the market. This article outlines the proposed project formulated to determine the efficacy and potency of these ARVs in generating immunity against rabies. The authors propose that this project will be articulated in three main categories. Part I will be the immunogenicity measurement using, New Zealand White rabbits as the animal model. Part II will be a field study with a sample dog population, including domestic and free-roaming dogs and Part III will be the potency testing of the ARVs using the mouse challenge test. Immunogenicity will be assessed by measuring the humoral immunity development following vaccination, using the methods of Florescent Antibody Virus Neutralization (FAVN) and ELISA. The project will be conducted in collaboration with WHO/WOAH Reference Laboratory for Rabies in Nancy, France, and Medical Research Institute, Colombo 08, Sri Lanka.
- 29 December 2023
- Published by The Physiological Society of India in INDIAN JOURNAL OF PHYSIOLOGY AND ALLIED SCIENCES
- Vol. 75 (04) , 47-56
Open AccessDetermination of immunogenicity and potency of canine anti-rabies vaccines marketed in Sri Lanka: A Proposal on an experimental study using rabbits as the animal model and field study using sample dog population.
Anti-rabies vaccines (ARVs) with good immunogenic capacity play an important role in controlling the deadly zoonotic rabies in Sri Lanka. The ARVs currently marketed in the country have not been tested for their efficacy and potency at the local level before being released to the market. This article outlines the proposed project formulated to determine the efficacy and potency of these ARVs in generating immunity against rabies. The authors propose that this project will be articulated in three main categories. Part I will be the immunogenicity measurement using, New Zealand White rabbits as the animal model. Part II will be a field study with a sample dog population, including domestic and free-roaming dogs and Part III will be the potency testing of the ARVs using the mouse challenge test. Immunogenicity will be assessed by measuring the humoral immunity development following vaccination, using the methods of Florescent Antibody Virus Neutralization (FAVN) and ELISA. The project will be conducted in collaboration with WHO/WOAH Reference Laboratory for Rabies in Nancy, France, and Medical Research Institute, Colombo 08, Sri Lanka.
- Open Access
Potency of Veterinary Rabies Vaccines Marketed in Sri Lanka
Seven brands of veterinary rabies vaccines are commercially available in Sri Lanka, but there is no established procedure to test the potency of the vaccines at the local level, especially prior to their release. The aim of this study was to test the potency of these vaccines using a mouse challenge test in collaboration with the EU/WOAH/WHO Reference Laboratory for Rabies, ANSES-Nancy, France. Based on the European Pharmacopoeia, the inactivated rabies vaccines complied with the mouse potency test if the estimated potency is ≥1.0 IU in the smallest prescribed dose. Among the eight tested vaccines, four single-dose preparations (Rabisin™, Raksharab™, Nobivac™ RL, and Nobivac™ Rabies) were compliant, with potencies of 12 IU/dose, 7.2 IU/dose, 4.4 IU/dose, and 3.4 IU/dose, respectively. Three of the single-dose preparations (Canvac™ R, Defensor™ 3, and Rabies killed vaccine) were not compliant, with potency values <1.0 IU/dose. One multidose preparation (Raksharab™ multidose) had a potency of 1.3 IU/dose, even though the test was not validated. Based on these results, it appears that some rabies vaccine batches that are currently available in the local market do not comply with the mouse potency test. Testing the vaccines’ potency before registration and release to the market appears to be an important step to allow good immunization to animals during pre-exposure vaccination programs.
Open AccessPotency of Veterinary Rabies Vaccines Marketed in Sri Lanka
Seven brands of veterinary rabies vaccines are commercially available in Sri Lanka, but there is no established procedure to test the potency of the vaccines at the local level, especially prior to their release. The aim of this study was to test the potency of these vaccines using a mouse challenge test in collaboration with the EU/WOAH/WHO Reference Laboratory for Rabies, ANSES-Nancy, France. Based on the European Pharmacopoeia, the inactivated rabies vaccines complied with the mouse potency test if the estimated potency is ≥1.0 IU in the smallest prescribed dose. Among the eight tested vaccines, four single-dose preparations (Rabisin™, Raksharab™, Nobivac™ RL, and Nobivac™ Rabies) were compliant, with potencies of 12 IU/dose, 7.2 IU/dose, 4.4 IU/dose, and 3.4 IU/dose, respectively. Three of the single-dose preparations (Canvac™ R, Defensor™ 3, and Rabies killed vaccine) were not compliant, with potency values <1.0 IU/dose. One multidose preparation (Raksharab™ multidose) had a potency of 1.3 IU/dose, even though the test was not validated. Based on these results, it appears that some rabies vaccine batches that are currently available in the local market do not comply with the mouse potency test. Testing the vaccines’ potency before registration and release to the market appears to be an important step to allow good immunization to animals during pre-exposure vaccination programs.
- Open Access
- 1 January 2023
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 12 (2) , 97-106
Detection of immunity in sheep following anti-rabies vaccination
Rathnadiwakara H, et al. Clin Exp Vaccine Res. 2023 Apr;12(2):97-106. https://doi.org/10.7774/cevr.2023.12.2.97
- 1 January 2023
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 12 (2) , 97-106
Open AccessDetection of immunity in sheep following anti-rabies vaccination
Rathnadiwakara H, et al. Clin Exp Vaccine Res. 2023 Apr;12(2):97-106. https://doi.org/10.7774/cevr.2023.12.2.97
- Open Access
- 2 April 2022
- Published by Elsevier in Comparative Immunology, Microbiology and Infectious Diseases
- Vol. 86, 101803
Compatibility between a rabies vaccine and two canine combined vaccines against canine distemper, adenovirosis, parvovirosis, parainfluenza virus disease and leptospirosis, with or without canine coronavirus
- 2 April 2022
- Published by Elsevier in Comparative Immunology, Microbiology and Infectious Diseases
- Vol. 86, 101803
Open AccessCompatibility between a rabies vaccine and two canine combined vaccines against canine distemper, adenovirosis, parvovirosis, parainfluenza virus disease and leptospirosis, with or without canine coronavirus
- 1 September 2020
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 176, 106007
Successful Leptospira genotyping strategy on DNA extracted from canine biological samples
- 1 September 2020
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 176, 106007
Successful Leptospira genotyping strategy on DNA extracted from canine biological samples
- 20 September 2008
- Published by Wiley in Veterinary Record
- Vol. 163 (12) , 355-357
Ability of antibodies to two new caliciviral vaccine strains to neutralise feline calicivirus isolates from the uk
This study examined a panel of 110 uk field isolates of feline calicivirus ( fcv ) for susceptibility to cross‐neutralisation by a panel of eight antisera raised in cats infected with fcv strains F9, 255, fcvg1 and fcv431 . The pairs of antisera raised against F9 or 255, neutralised 20 and 21 per cent or 37 and 56 per cent of field strains of virus respectively. In contrast, the pairs of antisera raised against the newer vaccine strains fcvg1 or fcv431 neutralised 29 and 70 per cent or 67 and 87 per cent of field strains respectively. Antisera raised against the two newer strains, namely fcvg1 and fcv431 , neutralised a greater proportion of field strains of calicivirus than antisera raised against the older fcv vaccine strains F9 and 255.
- 20 September 2008
- Published by Wiley in Veterinary Record
- Vol. 163 (12) , 355-357
Ability of antibodies to two new caliciviral vaccine strains to neutralise feline calicivirus isolates from the uk
This study examined a panel of 110 uk field isolates of feline calicivirus ( fcv ) for susceptibility to cross‐neutralisation by a panel of eight antisera raised in cats infected with fcv strains F9, 255, fcvg1 and fcv431 . The pairs of antisera raised against F9 or 255, neutralised 20 and 21 per cent or 37 and 56 per cent of field strains of virus respectively. In contrast, the pairs of antisera raised against the newer vaccine strains fcvg1 or fcv431 neutralised 29 and 70 per cent or 67 and 87 per cent of field strains respectively. Antisera raised against the two newer strains, namely fcvg1 and fcv431 , neutralised a greater proportion of field strains of calicivirus than antisera raised against the older fcv vaccine strains F9 and 255.
- Open Access
- 1 June 1993
- Published by WOAH (World Organisation for Animal Health) in Scientific and Technical Review
- Vol. 12 (2) , 471-481
Control of bovine virus diarrhoea-mucosal disease in cattle : examples of the combined use of serological screening, viral antigen detection and vaccination
As part of the preparatory phase of a disease control programme in three herds infected with bovine virus diarrhoea-mucosal disease (BVD-MD) virus (demonstrated by virus isolation), initial serological screening was performed on all livestock older than six months (351 animals) by blocking enzyme-linked immunosorbent assay (ELISA) using a monoclonal antibody recognising a common epitope to the different strains of BVD-MD virus. The presence of immunotolerant, persistently-infected animals was strongly suspected, as a high percentage (334 = 95.2%) of cattle showed positive serological reactions, while the other members of the herd (17 = 4.8%) continued to give negative results, even after vaccination with a live vaccine. Whole blood samples from all cattle were then tested individually for viral antigen by an ELISA technique which had previously been tested successfully. As a result, a total of nine viraemic animals were identified in the three herds. A confirmatory test was performed by the reference amplification method on cell culture with virus identification using specific fluorescein isothiocyanate-labelled monoclonal antibodies. The identification and elimination of the persistently-infected animals led to the recovery of a negative serological status for the herds. It was therefore recommended that protective measures should be taken to avoid the reappearance of viraemic animals, involving vaccination and systematic viral testing before introducing any new animal into the herd. It was advisable that these measures should be maintained until all the potential reservoirs and vectors of BVD-MD virus are better known.
- 1 June 1993
- Published by WOAH (World Organisation for Animal Health) in Scientific and Technical Review
- Vol. 12 (2) , 471-481
Open AccessControl of bovine virus diarrhoea-mucosal disease in cattle : examples of the combined use of serological screening, viral antigen detection and vaccination
As part of the preparatory phase of a disease control programme in three herds infected with bovine virus diarrhoea-mucosal disease (BVD-MD) virus (demonstrated by virus isolation), initial serological screening was performed on all livestock older than six months (351 animals) by blocking enzyme-linked immunosorbent assay (ELISA) using a monoclonal antibody recognising a common epitope to the different strains of BVD-MD virus. The presence of immunotolerant, persistently-infected animals was strongly suspected, as a high percentage (334 = 95.2%) of cattle showed positive serological reactions, while the other members of the herd (17 = 4.8%) continued to give negative results, even after vaccination with a live vaccine. Whole blood samples from all cattle were then tested individually for viral antigen by an ELISA technique which had previously been tested successfully. As a result, a total of nine viraemic animals were identified in the three herds. A confirmatory test was performed by the reference amplification method on cell culture with virus identification using specific fluorescein isothiocyanate-labelled monoclonal antibodies. The identification and elimination of the persistently-infected animals led to the recovery of a negative serological status for the herds. It was therefore recommended that protective measures should be taken to avoid the reappearance of viraemic animals, involving vaccination and systematic viral testing before introducing any new animal into the herd. It was advisable that these measures should be maintained until all the potential reservoirs and vectors of BVD-MD virus are better known.